US › Healthcare

CNS Pharmaceuticals Inc (CNSP)

US · Healthcare · Biotechnology

$4.85-6.30%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.6M

EPS

$-0.38

EPS estimate

$-0.24

EPS came in at -0.38 against a street estimate of -0.24 — a miss of 58.3%.

Key statistics

Market cap

$7.8M

Forward P/E

0.0

P/B

0.41

Book value

$12.45

EPS (TTM)

$-17.90

52-week high

$10.54

52-week low

$1.90

50-day MA

$5.47

200-day MA

$4.64

Beta

1.02

Analyst view

Analysts rate CNS Pharmaceuticals Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Shareholding

Insiders

0.95%

Institutions

21.25%

Largest institutional holders

Fund	Stake
Ikarian Capital, LLC	9.29%
ADAR1 Capital Management LLC	4.79%
Stonepine Capital Management Llc	2.84%
BOOTHBAY FUND MANAGEMENT, LLC	0.93%
Vanguard Fiduciary Trust Co	0.70%
Vanguard Capital Management, LLC	0.48%
UBS Group AG	0.10%
Tower Research Capital LLC	0.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CNS Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.